KRAS and colorectal cancer: In colorectal cancer KRAS exons 12 and 13 mutations drive de novo or acquired resistance to anti-EGFR therapy [48] and KRAS and/or BRAF status may change with time between primary and metastatic lesions in colorectal cancer in 17% of patients [49].